NCT00664586View on ClinicalTrials.gov

A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

June 30, 2009

Conditions
Refractory Solid TumorsLymphoma
Interventions
DRUG

Terameprocol (EM-1421)

Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion

Trial Locations (1)

37203

The Sarah Cannon Cancer Center, Nashville

Sponsors
All Listed Sponsors
lead

Erimos Pharmaceuticals

INDUSTRY

NCT00664586 - A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter